PE16299A1 - Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores - Google Patents
Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptoresInfo
- Publication number
- PE16299A1 PE16299A1 PE1997001069A PE00106997A PE16299A1 PE 16299 A1 PE16299 A1 PE 16299A1 PE 1997001069 A PE1997001069 A PE 1997001069A PE 00106997 A PE00106997 A PE 00106997A PE 16299 A1 PE16299 A1 PE 16299A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazolinilamino
- formula
- compounds
- alpha
- imidazolinylaminoindol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H o ALQUILO; R2, R3, R4, R5, R6 Y R7 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, OH, TIO, NITRO, CN, AMINO, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 SEA 2-IMIDAZOLINILAMINO; EL ENLACE (a) ES UN ENLACE SIMPLE O DOBLE; UN COMPUESTO (I) NO ES 4-(2-IMIDAZOLINILAMINO)INDOL; SIENDO COMPUESTOS (I) PREFERIDOS: 6-(2-IMIDAZOLINILAMINO)-7-METILINDOL Y 3-CIANO-6-(2-IMIDAZOLINILAMINO)-7-METILINDOL. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE: UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, UN ANTIINFLAMATORIO, 4-(2-IMIDAZOLINILAMINO)INDOL, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS DE ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO Y ADICCION DE SUSTANCIAS, TRASTORNOS GASTROINTESTINALES, ULCERAS, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3177796P | 1996-11-25 | 1996-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE16299A1 true PE16299A1 (es) | 1999-03-12 |
Family
ID=21861336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997001069A PE16299A1 (es) | 1996-11-25 | 1997-11-25 | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores |
Country Status (23)
Country | Link |
---|---|
US (2) | US6162818A (es) |
EP (1) | EP0944621B1 (es) |
JP (1) | JP2001506981A (es) |
KR (1) | KR100395356B1 (es) |
CN (1) | CN1092652C (es) |
AR (1) | AR013875A1 (es) |
AT (1) | ATE275142T1 (es) |
AU (1) | AU735767B2 (es) |
BR (1) | BR9713542A (es) |
CA (1) | CA2271841C (es) |
CO (1) | CO4910149A1 (es) |
CZ (1) | CZ180599A3 (es) |
DE (1) | DE69730516T2 (es) |
ES (1) | ES2225998T3 (es) |
HU (1) | HUP9904215A3 (es) |
ID (1) | ID22812A (es) |
IL (1) | IL130024A (es) |
NO (1) | NO992470L (es) |
PE (1) | PE16299A1 (es) |
SK (1) | SK68399A3 (es) |
TR (1) | TR199901885T2 (es) |
WO (1) | WO1998023610A1 (es) |
ZA (1) | ZA9710577B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
ATE275142T1 (de) * | 1996-11-25 | 2004-09-15 | Procter & Gamble | 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten |
US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
WO2001005758A2 (en) * | 1999-07-15 | 2001-01-25 | Nps Allelix Corp. | Indoles and indazoles for the treatment of migraine |
WO2001040183A1 (en) * | 1999-12-03 | 2001-06-07 | Alcon Universal Ltd. | 1-aminoalkyl-1h-indoles for treating glaucoma |
US20030166732A1 (en) * | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
MY135686A (en) * | 2002-06-24 | 2008-06-30 | Schering Corp | Indole derivatives useful as histamine h3 antagonists |
KR20050072812A (ko) | 2002-11-07 | 2005-07-12 | 악조 노벨 엔.브이. | 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌 |
DE10332473A1 (de) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Epilepsie |
TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
CA2628570A1 (en) | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
CL2008000838A1 (es) * | 2007-03-23 | 2008-10-10 | Neuraxon Inc | Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
EP2320911B1 (en) * | 2008-08-01 | 2014-10-08 | Eye Therapies LLC | Vasoconstriction compositions and methods of use |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
WO2010065547A1 (en) * | 2008-12-01 | 2010-06-10 | Map Pharmaceuticals, Inc. | Inhalation delivery methods and devices |
WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
CH632268A5 (de) * | 1977-01-14 | 1982-09-30 | Sandoz Ag | Verfahren zur herstellung von neuen heterocyclylaminoderivaten. |
US4398028A (en) * | 1977-01-14 | 1983-08-09 | Sandoz Ltd. | Bicyclic heterocyclic amino derivatives |
US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
ATE275142T1 (de) * | 1996-11-25 | 2004-09-15 | Procter & Gamble | 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten |
-
1997
- 1997-11-21 AT AT97948289T patent/ATE275142T1/de not_active IP Right Cessation
- 1997-11-21 BR BR9713542-9A patent/BR9713542A/pt not_active IP Right Cessation
- 1997-11-21 DE DE69730516T patent/DE69730516T2/de not_active Expired - Lifetime
- 1997-11-21 WO PCT/US1997/020801 patent/WO1998023610A1/en not_active Application Discontinuation
- 1997-11-21 SK SK683-99A patent/SK68399A3/sk unknown
- 1997-11-21 JP JP52469398A patent/JP2001506981A/ja active Pending
- 1997-11-21 ID IDW990403D patent/ID22812A/id unknown
- 1997-11-21 TR TR1999/01885T patent/TR199901885T2/xx unknown
- 1997-11-21 AU AU54380/98A patent/AU735767B2/en not_active Ceased
- 1997-11-21 CZ CZ991805A patent/CZ180599A3/cs unknown
- 1997-11-21 ES ES97948289T patent/ES2225998T3/es not_active Expired - Lifetime
- 1997-11-21 CN CN97180036A patent/CN1092652C/zh not_active Expired - Fee Related
- 1997-11-21 IL IL13002497A patent/IL130024A/en not_active IP Right Cessation
- 1997-11-21 HU HU9904215A patent/HUP9904215A3/hu unknown
- 1997-11-21 EP EP97948289A patent/EP0944621B1/en not_active Expired - Lifetime
- 1997-11-21 KR KR10-1999-7004535A patent/KR100395356B1/ko not_active IP Right Cessation
- 1997-11-21 CA CA002271841A patent/CA2271841C/en not_active Expired - Fee Related
- 1997-11-24 CO CO97068609A patent/CO4910149A1/es unknown
- 1997-11-25 PE PE1997001069A patent/PE16299A1/es not_active Application Discontinuation
- 1997-11-25 ZA ZA9710577A patent/ZA9710577B/xx unknown
- 1997-11-25 AR ARP970105526A patent/AR013875A1/es unknown
-
1999
- 1999-04-13 US US09/290,731 patent/US6162818A/en not_active Expired - Lifetime
- 1999-05-21 NO NO992470A patent/NO992470L/no not_active Application Discontinuation
-
2000
- 2000-10-17 US US09/690,992 patent/US6395764B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CZ180599A3 (cs) | 1999-11-17 |
IL130024A (en) | 2002-12-01 |
AU5438098A (en) | 1998-06-22 |
TR199901885T2 (xx) | 1999-10-21 |
DE69730516D1 (de) | 2004-10-07 |
CN1238771A (zh) | 1999-12-15 |
ID22812A (id) | 1999-12-09 |
US6395764B1 (en) | 2002-05-28 |
WO1998023610A1 (en) | 1998-06-04 |
IL130024A0 (en) | 2000-02-29 |
CN1092652C (zh) | 2002-10-16 |
EP0944621B1 (en) | 2004-09-01 |
SK68399A3 (en) | 2000-07-11 |
AU735767B2 (en) | 2001-07-12 |
ATE275142T1 (de) | 2004-09-15 |
NO992470L (no) | 1999-07-26 |
ES2225998T3 (es) | 2005-03-16 |
HUP9904215A2 (hu) | 2000-06-28 |
CO4910149A1 (es) | 2000-04-24 |
ZA9710577B (en) | 1998-06-25 |
HUP9904215A3 (en) | 2002-01-28 |
EP0944621A1 (en) | 1999-09-29 |
NO992470D0 (no) | 1999-05-21 |
CA2271841C (en) | 2003-07-08 |
JP2001506981A (ja) | 2001-05-29 |
KR100395356B1 (ko) | 2003-08-21 |
DE69730516T2 (de) | 2005-09-01 |
US6162818A (en) | 2000-12-19 |
AR013875A1 (es) | 2001-01-31 |
KR20000069088A (ko) | 2000-11-25 |
BR9713542A (pt) | 2000-01-25 |
CA2271841A1 (en) | 1998-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE16299A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores | |
PE16399A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores | |
DK0771197T3 (da) | Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander | |
PE20020858A1 (es) | Indanil aminas aciladas | |
DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
RS50437B (sr) | Benzoilpirazoli i njihova primena u ulozi herbicida | |
PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
PE20010685A1 (es) | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 | |
EA200200208A1 (ru) | Синергитическая композиция | |
PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
NO20014529D0 (no) | Tetrahydropyranderivater og deres anvendelse som terapautiske midler | |
PE20030447A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion | |
PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
DK0772604T3 (da) | Trialzolforbindelser og deres anvendelse som dopamin-D3-ligander | |
PE20040698A1 (es) | Derivados de isoindolina | |
PE16599A1 (es) | Compuestos de (2-imidazolinilamino) benzoxazol utiles como agonistas de alfa-2 adrenoreceptores | |
PE20040267A1 (es) | Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas | |
PE20020144A1 (es) | Derivados de pleuromutilinas como agentes antibacterianos | |
BR0210170A (pt) | Agente herbicida contendo benzoilpirazol e protetores | |
AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
PE20001234A1 (es) | Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1 | |
PE47099A1 (es) | Compuestos de 2-imidazolinilaminoindazol utiles como agonistas de alfa-2 adrenoreceptores | |
PE20020436A1 (es) | Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |